drugset / Trial / NCT02533336

Summary

Over one year period in an area with universal coverage of LLIN and ACT provision as the first-line treatment of malaria, the investigators intend to evaluate the impact of DL on malaria transmission as measured by the incidence of malaria parasitemia, the prevalence of moderate to severe anemia, and entomological parameters. Information on the relative cost-effectiveness estimates of DL and the community acceptability of DL will also be measured.

Timeline

Start
2015-11-09
Primary completion
2016-08-31
Completion
2017-03-31

Outcome

Outcome not reported

Stopped: “futility ground”

Drugs

EvaluationDrugModalityDoseRoute
Subject abamectin Unknown — —
Subject fenpyroximate Unknown — —

Indications